Armata Pharmaceuticals/ARMP

$3.25

-1.81%
-
1D1W1MYTD1YMAX

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Ticker

ARMP

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Deborah Birx

Employees

66

Headquarters

Los angeles, United States

ARMP Metrics

BasicAdvanced
$119.65M
Market cap
-
P/E ratio
-$1.91
EPS
0.88
Beta
-
Dividend rate
$119.65M
0.87687
$5.26
$1.07
16.11K
1.163
-1.68%
-71.11%
-3,439.35%
-90.34%
26.419
-17.77%
-76.6%
76.55%

What the Analysts think about ARMP

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
146.15% upside
High $9.00
Low $7.00
$3.25
Current price
$8.00
Average price target

ARMP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,320% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.5M
25%
Net income
$-19.8M
-36.33%
Profit margin
-1,320%
-49.07%

ARMP Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 57.14%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.40
-$0.10
-$0.86
-$0.55
-
Expected
-$0.32
-$0.38
-$0.31
-$0.35
-$0.31
Surprise
25%
-73.33%
177.42%
57.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Armata Pharmaceuticals stock?

Armata Pharmaceuticals (ARMP) has a market cap of $119.65M as of April 13, 2024.

What is the P/E ratio for Armata Pharmaceuticals stock?

The price to earnings (P/E) ratio for Armata Pharmaceuticals (ARMP) stock is 0 as of April 13, 2024.

Does Armata Pharmaceuticals stock pay dividends?

No, Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Armata Pharmaceuticals dividend payment date?

Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders.

What is the beta indicator for Armata Pharmaceuticals?

Armata Pharmaceuticals (ARMP) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Armata Pharmaceuticals stock price target?

The target price for Armata Pharmaceuticals (ARMP) stock is $8, which is 146.15% above the current price of $3.25. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Armata Pharmaceuticals stock

Buy or sell Armata Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing